NeuroGenesis is a clinical-stage cellular therapy company focused on developing novel and effective treatments for neurodegenerative diseases. The company has established NG-01 as a proprietary method to transform a unique subpopulation of marrow-derived stem cells into bio-factories for sustained delivery of regenerative and neuroprotective proteins. By promoting myelin and neuronal regeneration, the NG-01 technology is optimized to treat neurodegenerative diseases such as progressive multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS). NG-01 has been studied extensively in several clinical trials including a successful double blind, randomized, placebo-controlled Phase 2 study for progressive MS, and two long term (up to 4 years) Phase 2a trials for Progressive MS and ALS.
To date, more than 160 progressive MS and ALS patients from around the world have been treated with this breakthrough therapeutic modality. Headquartered in Upstate NY, NeuroGenesis is steadily moving forward with a global, FDA-approved multi-site Phase 2b trial for secondary progressive multiple sclerosis, in partnership with major medical research centers in the United States and abroad.
